PTGX · Protagonist Therapeutics
AI read · Neutral
The AI's read
The report adds no new sales, trial results, or company forecasts. It repeats one analyst's view, so it does not show a change in Protagonist's business outlook.
Wedbush says to keep buying Protagonist Therapeutics and set the price target at $173.
Neutral
Wedbush kept its Buy rating and $173 price target for Protagonist. The report adds no new company results or trial information, so it does not change the outlook.
Get alerts for PTGX
Follow Protagonist Therapeutics (PTGX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for PTGXFree on the App Store and Google Play, or on the web.